Precigen Doses First Patient in Phase 1 Trial of PRGN-3005 for Advanced OC
News
Precigen has begun dosing participants in a Phase 1 trial testing its experimental therapy PRGN-3005 UltraCAR-T in patients with advanced, platinum-resistant ovarian, fallopian tube, or primary peritoneal cancer. The open-label ... Read more